Abstract

 View                 Download                 XML
Title Role of Prior Rituximab on Outcomes of Asct in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis
Authors Li Li
Description

The aim of this study was to investigate the impact of prior rituximab on the subsequent results of autologous stem cell transplantation (ASCT) for relapsed or primary refractory diffuse large B-cell lymphoma (DLBCL). The random-effect model was used with the relative risk (RR) as the measure indicator. Patients were divided into two groups according to whether rituximab was administered (R group) or not (No-R group) prior to ASCT. The meta-analyzed RR and 95% confidence interval in the R group versus the No-R group were: 0.83 (0.69,0.99), 0.84 (0.72,0.98), 0.94 (0.71,1.25) for two-, three-, five-year overall survival (OS); 0.91 (0.77,1.08), 0.85 (0.69,1.06), 0.85 (0.62,1.17) for two-, three-, and five-year progress free survival (PFS); 0.46 (0.27,0.80), 0.47 (0.29,0.76), 0.74 (0.15,3.52) for two-, three-, and five-year event free survival (EFS). The results show the treatment trend of pre-treating with first-line rituximab-containing therapy for relapsed or refractory DLBCL is more favorable than with ASCT-naive.

Back